| Budget Amount *help |
¥16,380,000 (Direct Cost: ¥12,600,000、Indirect Cost: ¥3,780,000)
Fiscal Year 2018: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2017: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2016: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
|
|---|
| Outline of Final Research Achievements |
Although sublingual immunotherapy (SLIT) is a curative treatment for allergic rhinitis, this treatment needs long period to archive clinical remission. In addition, some patients are resistant to the treatment. We sought to determine whether saliva is associated with the clinical effectiveness of SLIT in Japanese cedar pollinosis.Both monocytes and THP-1 cells produced substantial amounts of IL-10 in response to whole saliva. Levels of IL-10 produced by THP-1 cells in response to saliva collected prior to SLIT were significantly higher in asymptomatic patients than disease-onset patients following SLIT. Our results provide a basis for why the sublingual route is effective and preferable in allergen immunotherapy. Saliva-induced IL-10 levels produced by THP-1 cells may be a predictive marker for clinical remission after SLIT.
|
